vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Shoals Technologies Group, Inc. (SHLS). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $148.3M, roughly 1.2× Shoals Technologies Group, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 5.5%, a 7.9% gap on every dollar of revenue. On growth, Shoals Technologies Group, Inc. posted the faster year-over-year revenue change (38.6% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-11.3M). Over the past eight quarters, Shoals Technologies Group, Inc.'s revenue compounded faster (27.8% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Shoals Technologies Group is a leading provider of electrical balance of systems solutions for renewable energy and e-mobility. It supplies connectivity components for solar projects, energy storage systems and EV charging infrastructure, serving clients across North America, Europe and Asia-Pacific.
AMPH vs SHLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $148.3M |
| Net Profit | $24.4M | $8.1M |
| Gross Margin | 46.8% | 31.6% |
| Operating Margin | 19.4% | 11.7% |
| Net Margin | 13.3% | 5.5% |
| Revenue YoY | -1.8% | 38.6% |
| Net Profit YoY | -35.7% | 3.9% |
| EPS (diluted) | $0.51 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $148.3M | ||
| Q3 25 | $191.8M | $135.8M | ||
| Q2 25 | $174.4M | $110.8M | ||
| Q1 25 | $170.5M | $80.4M | ||
| Q4 24 | $186.5M | $107.0M | ||
| Q3 24 | $191.2M | $102.2M | ||
| Q2 24 | $182.4M | $99.2M | ||
| Q1 24 | $171.8M | $90.8M |
| Q4 25 | $24.4M | $8.1M | ||
| Q3 25 | $17.4M | $11.9M | ||
| Q2 25 | $31.0M | $13.9M | ||
| Q1 25 | $25.3M | $-282.0K | ||
| Q4 24 | $38.0M | $7.8M | ||
| Q3 24 | $40.4M | $-267.0K | ||
| Q2 24 | $37.9M | $11.8M | ||
| Q1 24 | $43.2M | $4.8M |
| Q4 25 | 46.8% | 31.6% | ||
| Q3 25 | 51.4% | 37.0% | ||
| Q2 25 | 49.6% | 37.2% | ||
| Q1 25 | 50.0% | 35.0% | ||
| Q4 24 | 46.5% | 37.6% | ||
| Q3 24 | 53.3% | 24.8% | ||
| Q2 24 | 52.2% | 40.3% | ||
| Q1 24 | 52.4% | 40.2% |
| Q4 25 | 19.4% | 11.7% | ||
| Q3 25 | 13.2% | 13.7% | ||
| Q2 25 | 24.2% | 14.4% | ||
| Q1 25 | 21.9% | 5.4% | ||
| Q4 24 | 24.2% | 15.4% | ||
| Q3 24 | 29.8% | 4.4% | ||
| Q2 24 | 30.3% | 18.7% | ||
| Q1 24 | 27.9% | 12.8% |
| Q4 25 | 13.3% | 5.5% | ||
| Q3 25 | 9.0% | 8.7% | ||
| Q2 25 | 17.8% | 12.5% | ||
| Q1 25 | 14.8% | -0.4% | ||
| Q4 24 | 20.4% | 7.3% | ||
| Q3 24 | 21.1% | -0.3% | ||
| Q2 24 | 20.8% | 11.9% | ||
| Q1 24 | 25.1% | 5.3% |
| Q4 25 | $0.51 | $0.05 | ||
| Q3 25 | $0.37 | $0.07 | ||
| Q2 25 | $0.64 | $0.08 | ||
| Q1 25 | $0.51 | $0.00 | ||
| Q4 24 | $0.74 | $0.04 | ||
| Q3 24 | $0.78 | $0.00 | ||
| Q2 24 | $0.73 | $0.07 | ||
| Q1 24 | $0.81 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $7.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $600.0M |
| Total Assets | $1.6B | $904.1M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $7.3M | ||
| Q3 25 | $276.2M | $8.6M | ||
| Q2 25 | $231.8M | $4.7M | ||
| Q1 25 | $236.9M | $35.6M | ||
| Q4 24 | $221.6M | $23.5M | ||
| Q3 24 | $250.5M | $11.1M | ||
| Q2 24 | $217.8M | $3.2M | ||
| Q1 24 | $289.6M | $15.2M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | $141.8M | ||
| Q4 24 | $601.6M | $141.8M | ||
| Q3 24 | $596.4M | $141.8M | ||
| Q2 24 | $586.9M | $146.8M | ||
| Q1 24 | $594.0M | $168.8M |
| Q4 25 | $788.8M | $600.0M | ||
| Q3 25 | $776.7M | $589.6M | ||
| Q2 25 | $757.5M | $575.4M | ||
| Q1 25 | $751.3M | $558.9M | ||
| Q4 24 | $732.3M | $556.8M | ||
| Q3 24 | $727.7M | $545.2M | ||
| Q2 24 | $713.3M | $544.6M | ||
| Q1 24 | $672.4M | $554.0M |
| Q4 25 | $1.6B | $904.1M | ||
| Q3 25 | $1.7B | $851.8M | ||
| Q2 25 | $1.6B | $795.0M | ||
| Q1 25 | $1.6B | $788.4M | ||
| Q4 24 | $1.6B | $793.1M | ||
| Q3 24 | $1.5B | $801.3M | ||
| Q2 24 | $1.5B | $788.4M | ||
| Q1 24 | $1.6B | $825.3M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | 0.25× | ||
| Q4 24 | 0.82× | 0.25× | ||
| Q3 24 | 0.82× | 0.26× | ||
| Q2 24 | 0.82× | 0.27× | ||
| Q1 24 | 0.88× | 0.30× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-4.1M |
| Free Cash FlowOCF − Capex | $24.6M | $-11.3M |
| FCF MarginFCF / Revenue | 13.4% | -7.6% |
| Capex IntensityCapex / Revenue | 4.5% | 4.8% |
| Cash ConversionOCF / Net Profit | 1.35× | -0.50× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-16.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-4.1M | ||
| Q3 25 | $52.6M | $19.4M | ||
| Q2 25 | $35.6M | $-13.8M | ||
| Q1 25 | $35.1M | $15.6M | ||
| Q4 24 | $29.0M | $14.0M | ||
| Q3 24 | $60.0M | $15.7M | ||
| Q2 24 | $69.1M | $37.8M | ||
| Q1 24 | $55.3M | $12.9M |
| Q4 25 | $24.6M | $-11.3M | ||
| Q3 25 | $47.2M | $9.0M | ||
| Q2 25 | $25.0M | $-26.0M | ||
| Q1 25 | $24.4M | $12.3M | ||
| Q4 24 | $16.6M | $12.5M | ||
| Q3 24 | $46.2M | $13.3M | ||
| Q2 24 | $63.1M | $35.8M | ||
| Q1 24 | $46.5M | $10.4M |
| Q4 25 | 13.4% | -7.6% | ||
| Q3 25 | 24.6% | 6.6% | ||
| Q2 25 | 14.3% | -23.5% | ||
| Q1 25 | 14.3% | 15.4% | ||
| Q4 24 | 8.9% | 11.6% | ||
| Q3 24 | 24.1% | 13.0% | ||
| Q2 24 | 34.6% | 36.1% | ||
| Q1 24 | 27.1% | 11.4% |
| Q4 25 | 4.5% | 4.8% | ||
| Q3 25 | 2.8% | 7.7% | ||
| Q2 25 | 6.1% | 11.0% | ||
| Q1 25 | 6.3% | 4.0% | ||
| Q4 24 | 6.7% | 1.4% | ||
| Q3 24 | 7.2% | 2.3% | ||
| Q2 24 | 3.3% | 2.0% | ||
| Q1 24 | 5.1% | 2.7% |
| Q4 25 | 1.35× | -0.50× | ||
| Q3 25 | 3.03× | 1.63× | ||
| Q2 25 | 1.15× | -1.00× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 1.79× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 3.21× | ||
| Q1 24 | 1.28× | 2.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SHLS
| System Solutions | $122.0M | 82% |
| Components | $26.3M | 18% |
